Neuberger Berman Group LLC Buys New Holdings in NewLink Genetics Corp (NLNK)

Neuberger Berman Group LLC bought a new stake in NewLink Genetics Corp (NASDAQ:NLNK) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 30,000 shares of the biotechnology company’s stock, valued at approximately $305,000. Neuberger Berman Group LLC owned approximately 0.08% of NewLink Genetics as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in NewLink Genetics by 1,823.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock worth $105,000 after buying an additional 9,735 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in NewLink Genetics during the third quarter worth about $114,000. State of Wisconsin Investment Board purchased a new stake in NewLink Genetics during the second quarter worth about $125,000. Advisor Group Inc. boosted its holdings in NewLink Genetics by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after buying an additional 600 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in NewLink Genetics by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after buying an additional 556 shares in the last quarter. 52.63% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently commented on NLNK. Stifel Nicolaus boosted their price objective on shares of NewLink Genetics from $14.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, September 11th. Cantor Fitzgerald reissued a “buy” rating and set a $26.00 price objective on shares of NewLink Genetics in a report on Friday, September 8th. ValuEngine downgraded shares of NewLink Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. Robert W. Baird raised shares of NewLink Genetics from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $8.00 to $22.00 in a report on Friday, September 8th. Finally, Jefferies Group raised shares of NewLink Genetics from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $7.00 to $26.00 in a report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $23.29.

Shares of NewLink Genetics Corp (NASDAQ NLNK) opened at $10.06 on Friday. NewLink Genetics Corp has a fifty-two week low of $5.90 and a fifty-two week high of $25.17. The stock has a market cap of $364.39, a PE ratio of -4.12 and a beta of 1.10.

TRADEMARK VIOLATION WARNING: “Neuberger Berman Group LLC Buys New Holdings in NewLink Genetics Corp (NLNK)” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2018/01/05/neuberger-berman-group-llc-buys-new-holdings-in-newlink-genetics-corp-nlnk.html.

NewLink Genetics Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply